| | | | CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial
Press Release |
|
Utrecht and Schiphol, the Netherlands (19 May 2020) - InteRNA Technologies B.V. ("InteRNA") and CATO SMS ("CATO SMS"), a full-service regulatory and clinical CRO specialized in oncology, today announced that both organizations signed an agreement in which CATO SMS will conduct the Phase I clinical trial with microRNA mimic INT-1B3 in patients with advanced solid tumors.
InteRNA is advancing its lead compound INT-1B3 into the clinic. INT-1B3 is a chemically modified miR-193a-3p mimic that holds great promise based on its unique mechanism of action addressing multiple hallmarks of cancer simultaneously. It directly targets tumor cells and the tumor microenvironment by specific modulation of multiple signaling pathway components across... Read more |
|
| About CATO SMS: CATO SMS is a full-service clinical and regulatory contract research organization (CRO), specializing in complex areas such as (immuno-)oncology, advanced therapeutics and orphan diseases. CATO SMS has a center of excellence solely dedicated to oncology. With over 320 dedicated professionals with offices and operations in over 25 countries around the globe, the company brings a powerful blend of capabilities focused on supporting small and mid-sized biotech, top-tier pharmaceutical companies and investigator groups with their innovative research. We offer regulatory consulting and oncology drug development affairs in addition to clinical trial management services, with offices strategically located in close proximity from the FDA and EMA. |
|
|
|
| | | | |
|
